Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma-Reference-Cited by-同舟云学术

Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma

Published:2019-02-27 Issue:7 Volume:58 Page:e138-e140
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatol

Author:

Cinotti Elisa¹,Fiorani Diletta¹,Provvidenziale Luca¹,Miracco Clelia²,Calamai Vanessa³,Danielli Riccardo³,Rubegni Pietro¹

Affiliation:

1. Dermatology Unit Department of Medical, Surgical and Neurological Science University of Siena S. Maria alle Scotte Hospital Siena Italy

2. Pathology Unit Department of Medical, Surgical and Neurological Science University of Siena S. Maria alle Scotte Hospital Siena Italy

3. Medical Oncology and Immunotherapy Unit Department of Medical, Surgical and Neurological Science University of Siena S. Maria alle Scotte Hospital Siena Italy

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.14415

Reference10 articles.

1. It is finally time for adjuvant therapy in melanoma

2. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side‐effects of anti‐PD‐1 therapy;Hofmann L;Eur J Cancer,1990

3. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort

4. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab)

5. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Les porokératoses;Annales de Dermatologie et de Vénéréologie - FMC;2024-07

2. Porokeratoses—A Comprehensive Review on the Genetics and Metabolomics, Imaging Methods and Management of Common Clinical Variants;Metabolites;2023-11-26

3. Histopathologic findings of drug‐induced eruptive porokeratosis under nivolumab therapy;Journal of Cutaneous Pathology;2023-02-07

4. Pembrolizumab associated Stevens–Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma;Australasian Journal of Dermatology;2021-08-31

5. Drugs associated with development of porokeratosis: A systematic review;Dermatologic Therapy;2020-12